The application for the 11th annual installment of Endocrine Society’s Type 1 Diabetes Fellows series is now closed. Applicants will receive notifications and more details by no later than mid-March. Fellows that are invited to attend the in-person meeting will receive a promotional code for complimentary registration to ENDO 2024, as well as a travel stipend. To avoid any issues, we kindly request that applicants refrain from registering for the conference until after they have heard back about their application. Non-accepted applicants will be provided a promo code.
As in years past, the Type 1 Diabetes Fellows Program will have two core components:
On-demand didactic sessions; and
A prestigious, in-person meeting held in Boston, MA, May 30-31, ahead of ENDO, where fellows get the exclusive opportunity to meet with experts in T1D and product demonstrations with industry representatives.
Travel Visas
All individuals traveling from outside the United States must apply for entry visas as soon as possible and at least four months prior to the date of travel for ENDO 2024. The most updated information may be found at the U.S. State Department website. Scientists visiting the U.S. may find helpful information at The National Academies of Sciences website. Visa appointment wait times can be found here.
Please do not wait until to hear about your application or until ENDO 2024 registration opens in January 2024 before applying for a visa. All visitors traveling to the U.S. from visa waiver countries (i.e., Europe, Japan, Australia, etc.) must meet all requirements. If you need more information on the Electronic System for Travel Authorization (ESTA) or a list of visa waiver countries, click here. For information on the anticipated timeline, please visit the State Department website.
T1D in Underserved Populations: Lorena Wright, MD, University of Washington School of Medicine
The Pathogenesis of T1D: The Future for Preserving Beta Cell Function: Mark Atkinson, PhD, University of Florida
Applying New Billing Rules to Outpatient Diabetes Care: Carol Wysham, MD, Rockwood Clinic PS
Stages of Diabetes: Carla J. Greenbaum, MD, Benaroya Research Institute
Preparing for Future Careers in Endocrinology: What I Wish I was Told When I Left my Fellowship: Luisa Duran, MD, John Muir Health
Newly Diagnosed of Type 1 Diabetes: Irl B. Hirsch, MD, University of Washington
Hypoglycemia in T1D: Risks and Practical Prevention Strategies: Elizabeth Seaquist, MD, University of Minnesota
T1D and the Prevention and Treatment of Macrovascular Disease: Robert H. Eckel, MD, University of Colorado
The Endocrinologist’s Role in Screening and Managing Microvascular Disease: Janet McGill, MD, MA, FACE, Washington University in St. Louis
Identifying and Confronting Challenging Transitions: Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital
Developmental Considerations for Youth with T1D and Their Families: Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University
Type 1 Diabetes in Pregnancy: Before, During, and After: Camille Powe, MD, Massachusetts General Hospital
Adjunctive Therapies for T1D: Anne Peters, MD, USC Westside Center for Diabetes
Learning Objectives
Upon successful completion these educational initiatives, participants should be better able to:
Discuss the prevalence and progression of type 1 diabetes to recognize signs and differentially diagnose diabetes
Devise individualized treatment strategies that use new and emerging insulin therapies to manage individuals with type 1 diabetes with and without common comorbid conditions.
Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with type 1 diabetes and evaluate data from those technologies.
Recognize and evaluate individuals with type 1 diabetes for signs of depression and distress using updated guidelines and practice tools.
Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve care, long-term outcomes, and sick day management of individuals with type 1 diabetes.
Describe current and emerging therapy for the treatment of pre-clinical type 1 diabetes
Discuss various strategies for exercise and minimizing hypoglycemia for individuals with T1D